GELS (gelteq.com) Market Value to Book Value Ratio

gelteq.com (GELS) - corporate logo

Gelteq Limited (GELS) management is focused on validating drug efficacy and preparing for commercialization, while market confidence remains stable. This chart shows the market price, currently at 0.53, which correlates with successes in developing gel delivery systems and test results. The business relies on a non-cyclical model that is independent of economic phases and possesses high macro-resilience.

Market Capitalization to Net Assets: gelteq.com (GELS) for 10/30/2024 - 10/28/2026

GELS (Gelteq Limited): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart gelteq.com|GELS - Analyst Median Target
- market capitalization data:
Market Value Gelteq Limited Inc|GELS - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Gelteq|GELS - Net Asset Value|Market Capitalization to Book Value Ratio gelteq.com|GELS - Company Assets
- debt and liquidity data:
Total Debt to Capital Gelteq Limited|GELS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital gelteq.com|GELS - Company Total Debt Obligations|Debts to Book Capitalization Gelteq Limited Inc
Initial company analysis:Gelteq Ltd - GELS
Finished products of Gelteq Limited

The investment attractiveness of Gelteq Limited (GELS) depends directly on the market recognition of its innovative biomedical developments. This market-to-book capitalization ratio compares the current share price with the company's net assets. An increasing ratio reflects a premium for the implementation of eco-friendly gel drug delivery systems. However, sharp spikes on the chart signal speculative overheating. A sustainable premium confirms the high efficiency of the company's ESG strategy.

Direct competitors

Vertex Pharmaceuticals - Market Value to Book Value Ratio|ALNY (alnylam.com) - Market Capitalization to Book Value|INSM: Market Value to Book Value Ratio|Market Capitalization to Book Value UTHR|BMRN - Market Value to Book Value Ratio|Market Capitalization to Net Assets BridgeBio Corp (BBIO)|BGM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio cogentbio.com COGT|XERS: Market Capitalization to Book Value Ratio|KROS - Market Cap to Net Assets Ratio|Arcturus Pharma - Market Capitalization to Book Value Ratio|Eton Corp (ETON) - Market Capitalization to Book Value|KMDA (Kamada Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio FULC|Market Value to Book Value Ratio Abeona Therapeutics (ABEO)|Market Value to Book Value Ratio mereobiopharma.com (MREO)|Market Capitalization to Book Value Ratio PLX|PLRX - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Applied Therapeutics|RNTX - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio AYTU|Chemomab Therapeutics Ltd. (CMMB) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio SRx Health Solutions Inc (SRXH)|Capitalization to Book Value Ratio Polyrizon Ltd. (PLRZ)|Aeterna Zentaris (AEZS) - Market Cap to Net Assets Ratio|Market Value to Book Value CYTH (cyclotherapeutics.com)|Inozyme Pharma (INZY) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Reneo Pharmaceuticals Inc. RPHM|Market Capitalization to Book Value Ratio Aeterna Zentaris (CSCI)